Quantcast

Latest Opioid Stories

2014-10-30 08:36:43

SAN FRANCISCO, Oct. 30, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call...

2014-10-27 16:28:51

- Henrico County Sheriff's Office to Receive First Donation - RICHMOND, Va., Oct. 27, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced a new donation program that will allow qualifying local law enforcement agencies to receive EVZIO(TM) naloxone auto-injectors without charge as part of the kaleo Cares program. EVZIO, approved by the U.S. Food and Drug Administration (FDA) on April 3, 2014, is an opioid antagonist...

2014-10-27 08:28:27

Data from Sublingual Sufentanil Development Program Highlights Analgesic Response Compared to IV Morphine in Young vs Elderly Adult Patients REDWOOD CITY, Calif., Oct. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the American College of Surgeons (ACS 2014) Clinical Congress October 26(th) to October 30(th), 2014 at the Moscone Center in San Francisco, CA. The annual ACS meeting is...

2014-10-23 16:25:56

Entrenchment of Current Analgesics and Increasing Cost Sensitivity Will Hamper Uptake of Emerging Acute Pain Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 23, 2014 /PRNewswire/ -- Decision Resources Group finds that the acute pain market will grow minimally from $12.7 billion in 2013 to $13.3 billion in 2023 across the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan), representing an annual...

2014-10-22 08:32:56

Pain Insights, Inc. releases a comprehensive market research study on the impact of hydrocodone rescheduling, Zohydro(TM) ER, and abuse-deterrent formulations on prescribers and the pain market. FAIRFIELD, N.J., Oct. 22, 2014 /PRNewswire/ -- Rescheduling of hydrocodone combination products (HCPs) will impel a major transformation in the pain market, according to a new primary market research study by Pain Insights, Inc., a firm providing market research and consultation exclusively in the...

2014-10-20 20:26:58

Painkiller addiction is on the rise in the U.S., but those suffering from chronic pain can find relief while limiting risk with Dr. Seyed Rezaian at the California Orthopaedic Medical Clinic LOS ANGELES, Oct. 20, 2014 /PRNewswire/ -- Chronic pain is a major concern in our modern society, with more than 31% of U.S. adults suffering from some type of neck or back pain, according to a 2012 Gallup-Healthways study. The effects of chronic pain can be severe, and even debilitating, leading many...

2014-10-16 08:31:24

Additional Capital Enable Company to Achieve Additional Milestones in its Business Plan NEW YORK, Oct. 16, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants...

2014-10-10 08:23:54

Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response REDWOOD CITY, Calif., Oct. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the upcoming American Society of Anesthesiologists (ASA 2014) meeting October 11(th) to October 15(th), 2014 at the Ernest N. Morial Convention Center in New Orleans, LA. The annual...

2014-10-09 08:28:41

Butrans® is now available for prescribing in five dosage strengths STAMFORD, Conn., Oct. 9, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced the U.S. commercial launch of the new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans are now available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. http://photos.prnewswire.com/prnvar/20100921/NY67262 Butrans is the first transdermal system that delivers seven days...

2014-10-06 12:29:49

New white paper released as hydrocodone is reclassified as a Schedule II drug ITASCA, Ill., Oct. 6, 2014 /PRNewswire-USNewswire/ -- Today the National Safety Council released a white paper, Evidence for the efficacy of pain medications, compiling research showing the combination of over-the-counter pain medications ibuprofen and acetaminophen are more effective at treating acute pain than opioid painkillers. As patients find that they are unable to refill their hydrocodone...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.